GSK flu shot hikes narcolepsy risk in adults, too, study says; J&J pulls 3.3M Tylenol bottles in Brazil;

 @FiercePharma: Forest Labs' Howard Solomon to retire from CEO job after 37 years up top, the last few rather stormy. More | Follow @FiercePharma

 @EricPFierce: GlaxoSmithKline says Aussie strong dollar, wages lead to 120 job cuts at packing plant in Australia. Article | Follow @EricPFierce

> GlaxoSmithKline's ($GSK) pandemic flu shot Pandemrix may put adults at increased risk for narcolepsy, a Finnish study finds, after previous research highlighted a potential risk in children. Report

> Johnson & Johnson ($JNJ) recalled more than 3.3 million bottles of Tylenol Drops in Brazil, the latest in a series of manufacturing flops for the company's consumer healthcare unit. Report

> Bayer HealthCare tapped Johannes Schubmehl as its new chief information officer. Report

> Possible API contamination at a Chinese contract manufacturer has triggered recalls by three Canadian drugmakers. Report

> The Indian government has set guidelines for drugmakers to comply with European standards for bulk-drug imports. Report

> Novartis' ($NVS) Sandoz unit recalled two lots of an injectable drug after contamination at an Austrian plant. Report

Medical Device News

 @FierceMedDev: Stryker, OrthoSensor renew knee replacement co-marketing agreement. More | Follow @FierceMedDev

 @MarkHFierce: 2013 nominations for the FMD Fierce 15 have begun. More | Follow @MarkHFierce

 @DamianFierce: The year is young, but med tech companies are already slashing thousands of jobs. Here's a look at the deepest cuts. Report | Follow @DamianFierce

> Eli Lilly, Corgenix ink cancer drug companion Dx deal. Article

> Boston Scientific's strong results fuel hope for renal denervation success. Story

Biotech News

 @FierceBiotech: Feature: Top 10 Biotech CEO Pay Packages of 2012. Special Report | Follow @FierceBiotech

 @JohnCFierce: A "rational" market finally develops an appetite for biotech IPOs. Story | Follow @JohnCFierce

 @RyanMFierce: Cash-strapped biotech Seaside Tx fails PhIII test for pioneering Fragile X drug. More | Follow @RyanMFierce

> Cardeas banks $34M round for PhII antibiotic. Item

> J&J taps top blockbusters in the pipeline, lays out global R&D strategy. Article

> FDA panel backs low-dose rollout of Merck's sleep drug suvorexant. News

> BTG snaps up new technologies in $420M deal splurge. More

Pharma Manufacturing News

> J&J consumer healthcare faces more issues, this time in Brazil. Item

> Glaxo packs up a tablet packaging line in Australia. More

> FDA cites Boehringer Ingelheim plant in Germany. Article

> Malaysia's Pharmaniaga slates drug plant in Saudi Arabia. Story

Vaccines News

> Sanofi edges closer to universal flu vaccine. More

> Pfizer points to pandemic potential of Prevnar 13. Item

> Inertia at Pakistan's NIH threatening vaccine programs. Article

> Old whooping cough vax linked with better protection. Story

> Analyst taps Bristol, Roche cancer immunotherapies for explosive growth. News

And Finally... Medicare has overhauled its payments for diagnostic tests, leaving some newer, innovative cancer tests out in the cold. Report

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.